


CLAIMS

1. A compound which is of formula (I)



(I)

wherein

Z₁ is N and Z₂ is CH, or

Z₁ is CH and Z₂ is N, or

Z₁ and Z₂ is N;

Z is CH or N;

A is a phenyl ring or a 5-12 membered heterocyclic ring;

R₁ is H, C₁₋₇ alkyl, C₃₋₇ cycloalkyl, C₃₋₇ cycloalkyl C₁₋₇ alkyl, C₁₋₇ alkoxy, C₁₋₇ alkyl carbonyl, amino, hydroxy, hydroxy C₁₋₇ alkyl, halo C₁₋₇ alkyl, C₁₋₇ alkylamino C₁₋₇ alkyl, -R₁₆-C(O)-R₁₇ or -E-R₆;

R₂ is H, halogen or C₁₋₇ alkyl;

B is a 5-12 membered carbocyclic ring and R₃ is halogen, C₁₋₇ alkyl, C₁₋₇ alkoxy, halo C₁₋₇ alkyl or halo C₁₋₇ alkoxy; or B is a 5-12 membered heterocyclic ring and R₃ is H, halogen, C₁₋₇ alkyl, C₁₋₇ alkoxy, halo C₁₋₇ alkyl or halo C₁₋₇ alkoxy;

R₄ is H, halogen, C₁₋₇ alkyl or oxo;

R₅ is H, -C(O)R₇, -SO₂R₈ or an optionally substituted 5-6 membered heterocyclic ring;

R₆ is an optionally substituted 5-6 membered heterocyclic ring;

R₇ is C₁₋₇ alkyl, C₂₋₇ alkenyl, C₁₋₇ alkoxy, C₁₋₇ alkoxy C₁₋₇ alkyl, carboxy C₁₋₇ alkyl, C₁₋₇ alkoxy carbonyl C₁₋₇ alkyl, C₁₋₇ alkylamino C₁₋₇ alkyl, -NH-R₁₀ or -NH-X₁-R₁₁;

R₈ is C₁₋₇ alkyl, C₂₋₇ alkenyl, C₃₋₇ cycloalkyl, hydroxy C₁₋₇ alkyl, -NR₁₃R₁₄, -NH-X₂-R₁₅, phenyl or an optionally substituted 5-6 membered heterocyclic ring;

R₁₀ is C₁₋₇ alkyl or C₃₋₇ cycloalkyl;

R₁₁ is phenyl or an optionally substituted 5-6 membered heterocyclic ring;

R₁₃ and R₁₄ are, independently, H, C₁₋₇ alkyl or C₃₋₇ cycloalkyl;
 R₁₅ is phenyl or an optionally substituted 5-6 membered heterocyclic ring;
 R₁₆ is a bond or a C₁₋₇ alkyl;
 R₁₇ is C₁₋₇ alkyl, C₁₋₇ alkoxy, C₁₋₇ alkylamino, amino or hydroxy;
 E is a bond or a C₁₋₇ alkyl;
 X₁ and X₂ are, independently, a bond or C₁₋₇ alkyl;
 or is a pharmaceutically acceptable salt thereof.


2. A compound according to claim 1, wherein Z is CH.

3. A compound according to claim 1 or 2, wherein Z₁ is N and Z₂ is CH.


4. A compound according to claim 1 or 2, wherein Z₁ is CH and Z₂ is N.

5. A compound according to claim 1 or 2, wherein Z₁ and Z₂ is N.

6. A compound according to any of claims 1 to 5, wherein ring A is any one of the following groups or tautomers thereof



7. A compound according to any of claims 1 to 6, wherein ring B is any one of the following groups or tautomers thereof



8. A compound according to any of claims 1 to 7, wherein

A is a ring of formula (1'), (2'), (3'), (4'), (5'), (7'), (14'), (16') or (20');

5 R_1 is H, C_{1-7} alkyl, C_{1-7} alkoxy, hydroxy C_{1-7} alkyl, C_{1-7} alkylamino C_{1-7} alkyl or -E- R_6 ;


R_2 is H;

Z is CH;

B is a ring of formula (1''), (2''), (3''), (4'') or (6'');

10 E is a bond or C_{1-7} alkyl;


R_6 is any of the following groups



R_3 is H, halogen, C_{1-7} alkyl, C_{1-7} alkoxy;

15 R_4 is H or halogen;

R_5 is $-C(O)R_7$ or $-SO_2R_8$ or any one of the following groups



R_7 is C_{1-7} alkyl, C_{2-7} alkenyl or $-NH-R_{10}$;

R_8 is C_{1-7} alkyl, C_{2-7} alkenyl, C_{3-7} cycloalkyl, hydroxy C_{1-7} alkyl or $-NR_{13}R_{14}$; and

20 R_{10} is C_{1-7} alkyl or C_{3-7} cycloalkyl.

9. A compound according to any of claims 1 to 8, wherein B is a ring of formula (1''), (3'') or (6'').

10. A compound according to any of claims 1 to 9, wherein A is a ring of formula (1'), (2'), (4'), (5') or (20'').

11. A compound according to any of claims 1 to 10, wherein R₅ is -SO₂R₈.

12. A compound according to any of claims 1 to 11, wherein Z is CH, Z₁ is N and Z₂ is CH, A is a ring of formula (1'), B is a ring of formula (1''), R₁ is C₁₋₇ alkyl, R₂ is H, R₃ is halogen, R₄ is H or halogen, R₅ is -SO₂R₈ and R₈ is C₁₋₇ alkyl or C₃₋₇ cycloalkyl.

13. A compound according to claim 1, wherein B is a 5-12 membered heterocyclic ring.

14. A compound according to claim 1, wherein R₃ is halogen, C₁₋₇ alkyl, C₁₋₇ alkoxy, halo C₁₋₇ alkyl or halo C₁₋₇ alkoxy.

15. A compound according to any of claims 1 to 12, which is

4-(2, 4-Difluorophenyl)-N-(1-methyl-1H-pyrazol-3-yl)-6-(5-(1-methyl-1H-pyrazol-4-yl)-1H-benzo[d]imidazol-1-yl) pyridin-2-amine;

N-(4-(2,4-difluorophenyl)-6-(5-(1-methyl-1H-pyrazol-4-yl)-1H-benzo[d]imidazol-1-yl)pyridin-2-yl)cyclopropanesulfonamide;

Sodium salt of imido form of N-(4-(2,4-difluorophenyl)-6-(5-(1-methyl-1H-pyrazol-4-yl)-1H-benzo[d]imidazol-1-yl)pyridin-2-yl)cyclopropanesulfonamide;

N-(4-(2,4-difluorophenyl)-6-(5-(1-methyl-1H-pyrazol-4-yl)-1H-benzo[d]imidazol-1-yl)pyridin-2-yl)methanesulfonamide;

N-(4-(2,4-difluorophenyl)-6-(5-(1-methyl-1H-pyrazol-4-yl)-1H-benzo[d]imidazol-1-yl)pyridin-2-yl)ethanesulfonamide;

Sodium salt of imido form of N-(4-(2,4-difluorophenyl)-6-(5-(1-methyl-1H-pyrazol-4-yl)-1H-benzo[d]imidazol-1-yl)pyridin-2-yl)ethanesulfonamide;

N-(4-(2,4-difluorophenyl)-6-(5-(1-methyl-1H-pyrazol-4-yl)-1H-benzo[d]imidazol-1-yl)pyridin-2-yl)propane-2-sulfonamide;

Imido form of N-(4-(2,4-difluorophenyl)-6-(5-(1-methyl-1H-pyrazol-4-yl)-1H-benzo[d]imidazol-1-yl)pyridin-2-yl)propane-2-sulfonamide;

N-(4-(2-fluorophenyl)-6-(5-(1-methyl-1H-pyrazol-4-yl)-1H-benzo[d]imidazol-1-yl)pyridin-2-yl)cyclopropanesulfonamide;

Sodium salt of imido form of N-(4-(2-fluorophenyl)-6-(5-(1-methyl-1H-pyrazol-4-yl)-1H-benzo[d]imidazol-1-yl)pyridin-2-yl)cyclopropanesulfonamide;

N-(4-(2-fluorophenyl)-6-(5-(1-methyl-1H-pyrazol-4-yl)-1H-benzo[d]imidazol-1-yl)pyridin-2-yl)methanesulfonamide;

5 N-(4-(2-fluorophenyl)-6-(5-(1-methyl-1H-pyrazol-4-yl)-1H-benzo[d]imidazol-1-yl)pyridin-2-yl)ethanesulfonamide;

Sodium salt of imido form of N-(4-(2-fluorophenyl)-6-(5-(1-methyl-1H-pyrazol-4-yl)-1H-benzo[d]imidazol-1-yl)pyridin-2-yl)ethanesulfonamide;

10 N-(4-(2-fluorophenyl)-6-(5-(1-methyl-1H-pyrazol-4-yl)-1H-benzo[d]imidazol-1-yl)pyridin-2-yl)propane-2-sulfonamide;

Sodium salt of imido form of N-(4-(2-fluorophenyl)-6-(5-(1-methyl-1H-pyrazol-4-yl)-1H-benzo[d]imidazol-1-yl)pyridin-2-yl)propane-2-sulfonamide;

N-(4-(4-fluorophenyl)-6-(5-(1-methyl-1H-pyrazol-4-yl)-1H-benzo[d]imidazol-1-yl)pyridin-2-yl)cyclopropanesulfonamide;

15 N-(4-(4-fluorophenyl)-6-(5-(1-methyl-1H-pyrazol-4-yl)-1H-benzo[d]imidazol-1-yl)pyridin-2-yl)methanesulfonamide;

N-(4-(4-fluorophenyl)-6-(5-(1-methyl-1H-pyrazol-4-yl)-1H-benzo[d]imidazol-1-yl)pyridin-2-yl)propane-2-sulfonamide;

20 Sodium salt of imido form of N-(4-(4-fluorophenyl)-6-(5-(1-methyl-1H-pyrazol-4-yl)-1H-benzo[d]imidazol-1-yl)pyridin-2-yl)propane-2-sulfonamide;

N-(3-fluoro-6'-(5-(1-methyl-1H-pyrazol-4-yl)-1H-benzo[d]imidazol-1-yl)-[2,4'-bipyridin]-2'-yl)cyclopropanesulfonamide;

N-(3-fluoro-6'-(5-(1-methyl-1H-pyrazol-4-yl)-1H-benzo[d]imidazol-1-yl)-[2,4'-bipyridin]-2'-yl)acetamide;

25 N-(4-(2,4-difluorophenyl)-6-(5-(1-(2-(dimethylamino)ethyl)-1H-pyrazol-4-yl)-1H-benzo[d]imidazol-1-yl)pyridin-2-yl)cyclopropanesulfonamide;

N-(4-(2-fluorophenyl)-6-(5-(1-methyl-1H-pyrazol-4-yl)-1H-benzo[d]imidazol-1-yl)pyrimidin-2-yl)cyclopropanesulfonamide;

30 N-(6-(5-(1H-pyrazol-1-yl)-1H-benzo[d]imidazol-1-yl)-4-(2,4-difluorophenyl)pyridin-2-yl)cyclopropanesulfonamide;

N-(3,5-difluoro-6'-(5-(1-methyl-1H-pyrazol-4-yl)-1H-benzo[d]imidazol-1-yl)-[2,4'-bipyridin]-2'-yl)cyclopropanesulfonamide;

N-(3,5-difluoro-6'-(5-(1-methyl-1H-pyrazol-4-yl)-1H-benzo[d]imidazol-1-yl)-[2,4'-bipyridin]-2'-yl)acetamide;

N-(4-(2-chlorophenyl)-6-(5-(1-methyl-1H-pyrazol-4-yl)-1H-benzo[d]imidazol-1-yl)pyridin-2-yl)cyclopropanesulfonamide;

5 N-(3-chloro-6'-(5-(1-methyl-1H-pyrazol-4-yl)-1H-benzo[d]imidazol-1-yl)-[2,4'-bipyridin]-2'-yl)cyclopropanesulfonamide;

N-(5-fluoro-6'-(5-(1-methyl-1H-pyrazol-4-yl)-1H-benzo[d]imidazol-1-yl)-[2,4'-bipyridin]-2'-yl)cyclopropanesulfonamide;

10 N-(6-(5-(1H-imidazol-1-yl)-1H-benzo[d]imidazol-1-yl)-4-(2,4-difluorophenyl)pyridin-2-yl)cyclopropanesulfonamide;

N-(4-(2,4-difluorophenyl)-6-(5-(1-(2-morpholinoethyl)-1H-pyrazol-4-yl)-1H-benzo[d]imidazol-1-yl)pyridin-2-yl)cyclopropanesulfonamide;

N-(4-(2,4-difluorophenyl)-6-(5-(1-(pyrrolidin-3-yl)-1H-pyrazol-4-yl)-1H-benzo[d]imidazol-1-yl)pyridin-2-yl)cyclopropanesulfonamide;

15 N-(4-(2,4-difluorophenyl)-6-(5-(1-ethyl-1H-1,2,3-triazol-4-yl)-1H-benzo[d]imidazol-1-yl)pyridin-2-yl)cyclopropanesulfonamide;

N-(4-(2,4-difluorophenyl)-6-(5-(1-methyl-1H-1,2,3-triazol-4-yl)-1H-benzo[d]imidazol-1-yl)pyridin-2-yl)cyclopropanesulfonamide;

20 N-(4-(2,4-difluorophenyl)-6-(5-(1-methyl-1H-imidazol-4-yl)-1H-benzo[d]imidazol-1-yl)pyridin-2-yl)cyclopropanesulfonamide;

N-(4-(2,4-difluorophenyl)-6-(5-(1-methyl-1H-pyrazol-4-yl)-1H-benzo[d]imidazol-1-yl)pyrimidin-2-yl) acetamide;

Ethyl 1-(1-(6-(cyclopropanesulfonamido)-4-(2,4-difluorophenyl)pyridin-2-yl)-1H-benzo[d]imidazol-5-yl)-1H-1,2,3-triazole-4-carboxylate;

25 N-(4-(2-(difluoromethoxy)-4-fluorophenyl)-6-(5-(1-methyl-1H-pyrazol-4-yl)-1H-benzo[d]imidazol-1-yl)pyridin-2-yl)cyclopropanesulfonamide;

N-(4-(2,4-difluorophenyl)-6-(5-(1-methyl-1H-pyrazol-4-yl)-1H-benzo[d]imidazol-1-yl)pyrimidin-2-yl)cyclopropanesulfonamide;

30 N-(6-(2,4-difluorophenyl)-4-(5-(1-methyl-1H-pyrazol-4-yl)-1H-benzo[d]imidazol-1-yl)pyridin-2-yl) cyclopropanesulfonamide;

or a pharmaceutically acceptable salt or tautomer thereof.

16. A pharmaceutical composition comprising a compound as defined in any one of claims 1 to 15 with a pharmaceutically acceptable carrier.

17. A compound as defined in any one of claims 1 to 15 for use in a method of
5 treatment of a condition, where FGFR kinase inhibition is desired.

18. A compound as defined in any one of claims 1 to 15 for use in a method of treatment of cancer.